Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer

Int J Biol Macromol. 2022 Dec 1;222(Pt A):562-572. doi: 10.1016/j.ijbiomac.2022.09.201. Epub 2022 Sep 25.

Abstract

Chemotherapy resistance is one of the most critical challenges in colorectal cancer (CRC) treatment. The occurrence and development of chemotherapy resistance closely related to the tumor immune microenvironment (TIME). As the most important immunosuppressive immune cells infiltrating into the TIME, macrophages are essential for chemotherapy resistance in CRC treatment. In this study, we found that a kind of fucoidan (FPS1M) induced macrophages differentiation to the M1 phenotype, and this transformation promoted cancer cells apoptosis both in vitro and in vivo. TNFα is a key mediator of FPS1M-induced tumorcidal activity of macrophages. Mechanistically, as a stimulator of TLR4, FPS1M enhanced macrophages glycolysis and regulated macrophages differentiation to the M1 phenotype by the activation of TLR4 mediated PI3K/AKT/mTOR signaling axis. In addition, FPS1M improved the immunosuppressed tumor microenvironment by increasing the infiltration of M1 macrophages in tumor tissue, which was conducive to improving the sensitivity of tumor to chemotherapy. Collectively, our findings demonstrated that FPS1M has the great potential to be used in tumor immunotherapy. The results also suggested that the combination of FPS1M with capecitabine is an alternative therapy method for colon cancer.

Keywords: Capecitabine; Fucoidan; Macrophages; TLR4; Tumor microenvironment.

MeSH terms

  • Capecitabine
  • Colonic Neoplasms* / drug therapy
  • Colonic Neoplasms* / pathology
  • Humans
  • Macrophages
  • Phosphatidylinositol 3-Kinases
  • Toll-Like Receptor 4*
  • Tumor Microenvironment

Substances

  • Capecitabine
  • fucoidan
  • Toll-Like Receptor 4
  • Phosphatidylinositol 3-Kinases